Paper1345950
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
Lancet, 1992. Cited by 358 papers, by iCite.
Cite this record
ConductScience Library. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Papers, record 1345950. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1345950
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Neoplasm Recurrence, Local | Major topic |
| Ovariectomy | Major topic |
| Tamoxifen | Major topic |
| Age Factors | |
| Aged | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Middle Aged | |
| Multicenter Studies as Topic | |
| Odds Ratio | |
| Randomized Controlled Trials as Topic | |
| Survival Analysis | |
| Time Factors |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03917082 | Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer | Background |
Source ClinicalTrials.gov
Comments and corrections5
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 1346672 | Adjuvant treatment in breast cancer. | https://conductscience.org/library/papers/1346672 | PubMed |
| Comment in | 1346673 | Adjuvant treatment in breast cancer. | https://conductscience.org/library/papers/1346673 | PubMed |
| Comment in | 1346675 | Adjuvant treatment in breast cancer. | https://conductscience.org/library/papers/1346675 | PubMed |
| Comment in | 1346677 | Adjuvant treatment in breast cancer. | https://conductscience.org/library/papers/1346677 | PubMed |
| Comment in | 14575997 | ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit. | https://conductscience.org/library/papers/14575997 | PubMed |
Cited by255
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 358 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42171656 | Evolutionary Antifragile Therapy Is a Treatment Strategy to Suppress Drug Resistance by Exploiting Dose-Response Convexity. | Cancer Res | 2026 | https://conductscience.org/library/papers/42171656 | PubMed |
| 41702715 | Research Waste, Redundancy and the Rise of the Machines: The Questionable Future of Systematic Reviews. | Drug Alcohol Rev | 2026 | https://conductscience.org/library/papers/41702715 | PubMed |
| 41634433 | Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer. | Nat Rev Clin Oncol | 2026 | https://conductscience.org/library/papers/41634433 | PubMed |
| 41303742 | Surgical Ovarian Suppression and Breast Cancer-What Do We Know About It? | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/41303742 | PubMed |
| 41000654 | Evolutionary antifragile therapy. | bioRxiv | 2025 | https://conductscience.org/library/papers/41000654 | PubMed |
| 40910735 | Prognostic Performance of the Residual Cancer Burden Index With Respect to Molecular Breast Cancer Subtypes. | Eur J Breast Health | 2025 | https://conductscience.org/library/papers/40910735 | PubMed |
| 39850811 | Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets. | Front Oncol | 2024 | https://conductscience.org/library/papers/39850811 | PubMed |
| 38912361 | Vascular Endothelial Growth Factor Expression by Immunohistochemistry as a Possible Indicator of Prognosis in Invasive Breast Carcinoma of No Special Type. | Int J Appl Basic Med Res | 2024 | https://conductscience.org/library/papers/38912361 | PubMed |
| 36909339 | The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness. | Front Endocrinol (Lausanne) | 2023 | https://conductscience.org/library/papers/36909339 | PubMed |
| 34935776 | Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients. | Clin Transl Radiat Oncol | 2022 | https://conductscience.org/library/papers/34935776 | PubMed |
| 34697301 | Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer. | Cell Death Dis | 2021 | https://conductscience.org/library/papers/34697301 | PubMed |
| 34191627 | Heterogeneity within molecular subtypes of breast cancer. | Am J Physiol Cell Physiol | 2021 | https://conductscience.org/library/papers/34191627 | PubMed |
| 33204149 | Resistance and Overcoming Resistance in Breast Cancer. | Breast Cancer (Dove Med Press) | 2020 | https://conductscience.org/library/papers/33204149 | PubMed |
| 32472445 | Breast cancer: are long-term and intermittent endocrine therapies equally effective? | J Cancer Res Clin Oncol | 2020 | https://conductscience.org/library/papers/32472445 | PubMed |
| 32089923 | Male Breast Cancer: Reevaluate Our Opinion. | Case Rep Oncol Med | 2020 | https://conductscience.org/library/papers/32089923 | PubMed |
| 32054043 | Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32054043 | PubMed |
| 31615089 | Clinical Theragnostic Relationship between Drug-Resistance Specific miRNA Expressions, Chemotherapeutic Resistance, and Sensitivity in Breast Cancer: A Systematic Review and Meta-Analysis. | Cells | 2019 | https://conductscience.org/library/papers/31615089 | PubMed |
| 30840336 | Endocrine-related quality of life in a randomized trial of exercise on aromatase inhibitor-induced arthralgias in breast cancer survivors. | Cancer | 2019 | https://conductscience.org/library/papers/30840336 | PubMed |
| 29721484 | Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant). | South Asian J Cancer | 2018 | https://conductscience.org/library/papers/29721484 | PubMed |
| 29312741 | Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated meta-analysis. | J Thorac Dis | 2017 | https://conductscience.org/library/papers/29312741 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Authors
- Grants
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1345950
GET https://conductscience.org/api/papers/v1/1345950/cited_by?page=2